Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

864.70INR
16 Nov 2018
Change (% chg)

Rs10.95 (+1.28%)
Prev Close
Rs853.75
Open
Rs857.90
Day's High
Rs869.90
Day's Low
Rs855.45
Volume
1,154,745
Avg. Vol
3,030,787
52-wk High
Rs986.10
52-wk Low
Rs723.65

Latest Key Developments (Source: Significant Developments)

India's Lupin Launches Generic Atovaquone Oral Suspension USP In U.S
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lupin Ltd ::LAUNCHES GENERIC ATOVAQUONE ORAL SUSPENSION USP IN THE U.S.  Full Article

India's Lupin Says Nagpur Facility Receives EIR From U.S FDA
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Lupin Ltd ::CO'S NAGPUR FACILITY RECEIVES EIR FROM US FDA.SAYS INSPECTION CONDUCTED IN SEPTEMBER 2018 CONCLUDED WITHOUT ANY OBSERVATIONS.  Full Article

India's Lupin Receives FDA Approval For Generic Triamcinolone Acetonide Ointment USP
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Lupin Ltd ::SAYS CO RECEIVES FDA APPROVAL FOR GENERIC TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.1 PERCENT.  Full Article

Lupin Neurosciences Announces Positive CHMP Opinion For Namuscla
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Lupin Ltd ::LUPIN NEUROSCIENCES ANNOUNCES POSITIVE CHMP OPINION FOR NAMUSCLA FOR TREATMENT OF MYOTONIA IN NON-DYSTROPHIC MYOTONIC DISORDERS.  Full Article

Lupin Says USFDA's Pithampur Unit-3 Inspection Closed With 5 Observations
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Lupin Ltd ::SAYS LUPIN'S PITHAMPUR UNIT-3 (INDORE) INSPECTED BY US FDA.INSPECTION CLOSED WITH FIVE OBSERVATIONS WHICH ARE PROCEDURAL IN NATURE.INSPECTION WAS A GMP INSPECTION FOR FACILITY AND ALSO A PRE-APPROVAL INSPECTION (PAI) FOR TIOTROPIUM DPI AND.  Full Article

Lupin Launches Generic Clobetasol Propionate Ointment USP 0.05% In U.S.
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Lupin Ltd ::SAYS LAUNCHES GENERIC CLOBETASOL PROPIONATE OINTMENT USP 0.05% IN THE U.S..  Full Article

Lupin And Eli Lilly Expand Partnership In India
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Lupin Ltd ::LUPIN AND LILLY PARTNER FOR IMPROVED ACCESS TO DIABETES TREATMENT IN INDIA.UNDER NEW PARTNERSHIP, LUPIN WILL DISTRIBUTE AND MARKET LILLY’S APLEVANT, A ONCE-WEEKLY INJECTION FOR TYPE 2 DIABETES TREATMENT.  Full Article

India's Lupin Starts Strategic Review Of Japanese Arm - Bloomberg
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - :INDIA'S LUPIN STARTS STRATEGIC REVIEW OF JAPANESE ARM - BLOOMBERG, CITING SOURCES.  Full Article

Lupin Says FDA Successfully Completed Inspection At Nagpur Facility
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Lupin Ltd ::SUCCESSFUL COMPLETION OF AN INSPECTION CARRIED OUT BY THE US FDA AT ITS NAGPUR, MAHARASHTRA, INDIA FACILITY.INSPECTION CONCLUDED WITHOUT ANY OBSERVATION.INSPECTION WAS A PRODUCT SPECIFIC PRE-APPROVAL INSPECTION.  Full Article

Lupin Says Gets FDA Approval For Generic Atovaquone Oral Solution
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES FDA APPROVAL FOR GENERIC ATOVAQUONE ORAL SOLUTION.  Full Article

UPDATE 1-India's Lupin Q2 profit dives as U.S. sales, higher expenses weigh

Oct 31 Lupin Ltd, India's second-largest drugmaker by revenue, posted a lower-than-expected second-quarter profit on Wednesday, as sales in the United States - a key market - dropped and overall manufacturing costs rose.